• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Arcus Biosciences Set to Join S&P SmallCap 600

    4/4/22 6:45:00 PM ET
    $CFG
    $ISBC
    $RCUS
    $SPGI
    Major Banks
    Finance
    Savings Institutions
    Finance
    Get the next $CFG alert in real time by email

    NEW YORK, April 4, 2022 /PRNewswire/ -- Arcus Biosciences Inc. (NYSE:RCUS) will replace Investors Bancorp Inc. (NASD:ISBC) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 7. S&P 500 constituent Citizens Financial Group Inc. (NYSE:CFG) is acquiring Investors Bancorp in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    April 7, 2022

    S&P SmallCap 600

    Addition

    Arcus Biosciences

    RCUS

    Health Care



    S&P SmallCap 600

    Deletion

    Investors Bancorp

    ISBC

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/arcus-biosciences-set-to-join-sp-smallcap-600-301517287.html

    SOURCE S&P Dow Jones Indices

    Get the next $CFG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CFG
    $ISBC
    $RCUS
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    Citizens Financial Group Inc.
    $CFG
    12/11/2025$60.00Outperform → Neutral
    Robert W. Baird
    Citizens Financial Group Inc.
    $CFG
    10/9/2025$65.00Neutral → Buy
    BofA Securities
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Citizens Financial Group Inc.
    $CFG
    9/29/2025$71.00Equal-Weight → Overweight
    Morgan Stanley
    Citizens Financial Group Inc.
    $CFG
    9/10/2025$61.00Overweight
    Cantor Fitzgerald
    Citizens Financial Group Inc.
    $CFG
    8/1/2025$52.00Neutral → Overweight
    Analyst
    Citizens Financial Group Inc.
    $CFG
    7/18/2025$55.00In-line → Outperform
    Evercore ISI
    Citizens Financial Group Inc.
    $CFG
    7/9/2025$57.00Mkt Perform → Outperform
    Keefe Bruyette
    More analyst ratings

    $CFG
    $ISBC
    $RCUS
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens Financial Group downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Citizens Financial Group from Outperform to Neutral and set a new price target of $60.00

    12/11/25 8:52:08 AM ET
    $CFG
    Major Banks
    Finance

    Citizens Financial Group upgraded by BofA Securities with a new price target

    BofA Securities upgraded Citizens Financial Group from Neutral to Buy and set a new price target of $65.00

    10/9/25 8:18:58 AM ET
    $CFG
    Major Banks
    Finance

    Seaport Research Partners initiated coverage on S&P Global with a new price target

    Seaport Research Partners initiated coverage of S&P Global with a rating of Buy and set a new price target of $540.00

    10/1/25 9:39:03 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $CFG
    $ISBC
    $RCUS
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 14th, 2026, at 3:00 pm PT. A live webcast of the presentation will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event. About Arcus Biosciences Arcus Bios

    12/18/25 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P 500 Q3 2025 Buybacks Post Modest 6.2% Gain to $249.0 Billion After Declining 20.1% Amidst Uncertainty in Q2; Q4 2025 Expenditures Expected to Post Similar Growth, As 2025 Anticipates a Record $1 Trillion

    S&P 500 Q3 2025 buybacks were $249.0 billion, as the expenditure increased 6.2% from Q2's $234.6 billion and down 15.1% from the record Q1 2025 $293.5 billion, and was up 9.9% from Q3 2024's $226.6 billionThe 12-month September 2025 expenditure was a record $1.020 trillion and was up 11.1% from the 12-month September 2024 expenditure of $918.4 billion Health Care and Financials significantly increased their spending, up 32.2% and 26.3% respectively over Q2 2025, as Materials and Real Estate reduced spending by 21.0% and 40.3%, respectivelyThe net buyback 1% tax reduced Q3 2025 operating earnings, which are set to post a quarterly earnings record by 0.36% and As Reported GAAP by 0.41%, as the

    12/18/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Launches StepForward: $10 Million Initiative Preparing Global Youth for AI-Enabled Futures

    Three-year philanthropic program will award grants to nonprofits focused on workforce readiness and AI education NEW YORK, Dec. 17, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the launch of StepForward, a new philanthropic initiative aimed at equipping the next generation with the skills needed to succeed in an AI-enabled workforce. Through StepForward, S&P Global and the S&P Global Foundation will invest $10 million over the next three years to support organizations delivering innovative workforce development programs for youth. The initiative will also lever

    12/17/25 2:30:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $CFG
    $ISBC
    $RCUS
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Markus Richard sold $210,144 worth of shares (9,546 units at $22.01), decreasing direct ownership by 13% to 65,647 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    12/18/25 5:35:37 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Tang Carolyn C. sold $318,496 worth of shares (14,468 units at $22.01), decreasing direct ownership by 10% to 124,734 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    12/18/25 5:35:45 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Azoy Alexander sold $195,434 worth of shares (8,832 units at $22.13), decreasing direct ownership by 32% to 18,531 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    12/18/25 5:35:29 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CFG
    $ISBC
    $RCUS
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:06:05 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:05:56 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/20/25 7:42:29 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CFG
    $ISBC
    $RCUS
    $SPGI
    SEC Filings

    View All

    Arcus Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Arcus Biosciences, Inc. (0001724521) (Filer)

    12/18/25 4:05:43 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    12/16/25 4:05:25 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form 144 filed by Arcus Biosciences Inc.

    144 - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/15/25 6:21:39 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CFG
    $ISBC
    $RCUS
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    S&P Global Adds Hubert Joly to its Board of Directors

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) announced today that its Board of Directors has approved the addition of Mr. Hubert Joly to the Board, effective January 2, 2026. Mr. Joly is the former Chair and Chief Executive Officer at Best Buy and is now a senior lecturer at Harvard Business School. Earlier in his career, Mr. Joly served as President and CEO of Carlson, a global hospitality and travel company. In addition to his teaching post at Harvard, Mr. Joly is a member of the Board of Directors of Johnson & Johnson and was until recently on the Board of

    12/16/25 8:05:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces Mobility Business Chief Financial Officer

    Matt Calderone, outgoing CFO of Booz Allen, named new CFO of Mobility and will lead the finance function of the standalone company NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Matt Calderone as Chief Financial Officer (CFO) of the Mobility business, joining the company by March 1, 2026. Mr. Calderone will serve as the CFO of the standalone public company through its planned separation from S&P Global and will oversee all aspects of the company's Finance function. He will report to Mr. Bill Eager, President of S&P Global Mobility, and CEO-designate of the future standalone company.

    12/16/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Corebridge Financial Set to Join S&P MidCap 400

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Corebridge Financial Inc. (NYSE:CRBG) will replace Allete Inc. (NYSE:ALE) in the S&P MidCap 400 effective prior to the open of trading on Wednesday, December 17. Canada Pension Plan Investment Board and Global Infrastructure Partners are acquiring Allete in a deal expected to close soon, pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 17, 2025 S&P MidCap 400 Addition Corebridge Financial CRBG Financials Dec 17, 2025 S&P MidCap 400 Deletion Allete ALE Utilities ABOUT S&P DOW JONES INDICES S

    12/12/25 5:51:00 PM ET
    $ALE
    $CRBG
    $SPGI
    Power Generation
    Utilities
    Life Insurance
    Finance

    $CFG
    $ISBC
    $RCUS
    $SPGI
    Financials

    Live finance-specific insights

    View All

    S&P 500 Q3 2025 Buybacks Post Modest 6.2% Gain to $249.0 Billion After Declining 20.1% Amidst Uncertainty in Q2; Q4 2025 Expenditures Expected to Post Similar Growth, As 2025 Anticipates a Record $1 Trillion

    S&P 500 Q3 2025 buybacks were $249.0 billion, as the expenditure increased 6.2% from Q2's $234.6 billion and down 15.1% from the record Q1 2025 $293.5 billion, and was up 9.9% from Q3 2024's $226.6 billionThe 12-month September 2025 expenditure was a record $1.020 trillion and was up 11.1% from the 12-month September 2024 expenditure of $918.4 billion Health Care and Financials significantly increased their spending, up 32.2% and 26.3% respectively over Q2 2025, as Materials and Real Estate reduced spending by 21.0% and 40.3%, respectivelyThe net buyback 1% tax reduced Q3 2025 operating earnings, which are set to post a quarterly earnings record by 0.36% and As Reported GAAP by 0.41%, as the

    12/18/25 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    KBW Announces Index Rebalancing for Fourth-Quarter 2025

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE:SF), announces the upcoming index rebalancing for the fourth quarter of 2025. This quarter, there are constituent changes within six of our indexes: KBW Nasdaq Insurance Index (Index Ticker: KIX), KBW Nasdaq Regional Banking Index (Index Ticker: KRX, ETF Ticker: KBWR), KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDX, ETF Ticker: KBWD), KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY), KBW Nasdaq Property and Casualty Ins

    12/12/25 8:30:00 PM ET
    $AAT
    $ACIW
    $AJG
    Real Estate Investment Trusts
    Real Estate
    Computer Software: Prepackaged Software
    Technology

    S&P Global Completes $1.8 Billion Acquisition of With Intelligence, Strengthening its Position as a Leader in Private Markets Data & Analytics

    Combination unlocks new market opportunities and cements S&P Global as one of the most comprehensive providers of private markets intelligence NEW YORK, Nov. 25, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the successful completion of its acquisition of With Intelligence, a leading source of private markets data, insights and analytics for $1.8 billion, from a group led by majority investor Motive Partners, a private investment firm focused exclusively on financial and tech-enabled business services companies. First announced in October, the deal significantly

    11/25/25 1:25:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $CFG
    $ISBC
    $RCUS
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Citizens Financial Group Inc.

    SC 13G - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Subject)

    11/13/24 12:52:42 PM ET
    $CFG
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by Citizens Financial Group Inc.

    SC 13G/A - CITIZENS FINANCIAL GROUP INC/RI (0000759944) (Subject)

    11/13/24 10:27:59 AM ET
    $CFG
    Major Banks
    Finance